Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Embolization, Therapeutic | 2 | 2023 | 224 | 0.760 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2022 | 10 | 0.730 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 54 | 0.690 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2025 | 86 | 0.410 |
Why?
|
| Thyroid Diseases | 1 | 2014 | 26 | 0.410 |
Why?
|
| Stents | 3 | 2025 | 784 | 0.350 |
Why?
|
| Nasal Obstruction | 1 | 2011 | 17 | 0.350 |
Why?
|
| Nasal Cavity | 1 | 2011 | 56 | 0.340 |
Why?
|
| Radiology | 3 | 2016 | 119 | 0.280 |
Why?
|
| Renal Dialysis | 2 | 2025 | 947 | 0.260 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2025 | 747 | 0.260 |
Why?
|
| Kidney Failure, Chronic | 2 | 2025 | 930 | 0.250 |
Why?
|
| Endovascular Procedures | 2 | 2025 | 778 | 0.250 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2025 | 474 | 0.220 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2025 | 14 | 0.220 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2025 | 15 | 0.220 |
Why?
|
| Ureteral Obstruction | 1 | 2025 | 87 | 0.210 |
Why?
|
| Fatty Liver | 1 | 2025 | 220 | 0.190 |
Why?
|
| Aneurysm, False | 1 | 2023 | 85 | 0.180 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 304 | 0.160 |
Why?
|
| Pulmonary Artery | 1 | 2022 | 437 | 0.140 |
Why?
|
| Constriction, Pathologic | 2 | 2025 | 222 | 0.130 |
Why?
|
| Computer-Assisted Instruction | 1 | 2016 | 58 | 0.120 |
Why?
|
| Radiation Protection | 1 | 2015 | 50 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2025 | 79 | 0.110 |
Why?
|
| Radiography, Interventional | 1 | 2015 | 78 | 0.110 |
Why?
|
| Radiation Exposure | 1 | 2015 | 45 | 0.110 |
Why?
|
| Vascular Patency | 2 | 2025 | 178 | 0.110 |
Why?
|
| Safety Management | 1 | 2015 | 111 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12821 | 0.100 |
Why?
|
| Occupational Exposure | 1 | 2015 | 133 | 0.100 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 101 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 180 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 203 | 0.100 |
Why?
|
| Prosthesis Design | 2 | 2025 | 623 | 0.090 |
Why?
|
| Pyriform Sinus | 1 | 2011 | 8 | 0.090 |
Why?
|
| Sampling Studies | 1 | 2011 | 76 | 0.090 |
Why?
|
| Physics | 1 | 2011 | 12 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2011 | 191 | 0.080 |
Why?
|
| Humans | 12 | 2025 | 130080 | 0.080 |
Why?
|
| Curriculum | 2 | 2016 | 792 | 0.080 |
Why?
|
| Educational Measurement | 1 | 2011 | 316 | 0.070 |
Why?
|
| Algorithms | 1 | 2014 | 1662 | 0.060 |
Why?
|
| Liver | 2 | 2025 | 1783 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 550 | 0.060 |
Why?
|
| Chile | 1 | 2025 | 25 | 0.060 |
Why?
|
| Observer Variation | 1 | 2025 | 311 | 0.050 |
Why?
|
| Ureter | 1 | 2025 | 84 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2057 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 3026 | 0.050 |
Why?
|
| Thrombin | 1 | 2023 | 58 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5167 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2011 | 3677 | 0.040 |
Why?
|
| Survival Rate | 2 | 2025 | 2107 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1482 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2025 | 942 | 0.040 |
Why?
|
| Risk Factors | 2 | 2025 | 10960 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17541 | 0.040 |
Why?
|
| Adult | 4 | 2025 | 31011 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 2891 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8554 | 0.030 |
Why?
|
| Aged | 3 | 2025 | 20821 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 1998 | 542 | 0.030 |
Why?
|
| Infant | 1 | 2011 | 13269 | 0.030 |
Why?
|
| Middle Aged | 3 | 2025 | 28314 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2011 | 15005 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 6165 | 0.030 |
Why?
|
| Perception | 1 | 2016 | 228 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 443 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 6765 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1998 | 711 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 668 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1439 | 0.020 |
Why?
|
| Students, Medical | 1 | 2016 | 346 | 0.020 |
Why?
|
| Melanoma | 1 | 1998 | 927 | 0.020 |
Why?
|
| Female | 3 | 2025 | 70246 | 0.020 |
Why?
|
| Male | 3 | 2025 | 64385 | 0.020 |
Why?
|
| Young Adult | 1 | 2023 | 9981 | 0.020 |
Why?
|
| Texas | 1 | 2015 | 3655 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2011 | 1217 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1998 | 55 | 0.010 |
Why?
|
| Injections | 1 | 1998 | 109 | 0.010 |
Why?
|
| Retroviridae | 1 | 1998 | 182 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 358 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1998 | 235 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 975 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1998 | 344 | 0.010 |
Why?
|
| United States | 1 | 2011 | 11897 | 0.010 |
Why?
|
| Adolescent | 1 | 1998 | 20801 | 0.000 |
Why?
|